Table 4 Relevance to clinicopathological characteristics and operative outcomes with LOX-1, CD163, and PD-1 expression

Sex

Male/ Female

22/ 7

9/ 3

1

18/ 6

10/ 3

1

22/ 5

8/ 3

0.667

Age(years-old)

71.0 (65.0-73.0)

72.5 (69.0-78.3)

0.295

72.0 (69.8-76.8)

71.0 (67.0-73.0)

0.202

71.0 (67.5-72.5)

75.0 (72.0-79.0)

0.032*

Tumor size (mm)

40.0 (30.0-65.0)

50.0 (40.0-87.0)

0.240

40.0 (28.0-61.3)

45.0 (30.0-56.0)

0.556

40.0 (27.5-62.5)

45.0 (32.5-63.0)

0.640

Comorbidities

absent/ present

3/ 26

3/ 9

0.334

4/ 20

2/ 11

1

4/ 23

2/ 9

1

Other cancer history

absent/ present

20/ 9

7/ 5

0.719

16/ 8

8/ 5

1

17/ 10

8/ 3

0.714

Preoperative NLR

2.17 (1.79-2.97)

3.23 (2.54-4.45)

0.037*

2.17 (1.79-3.01)

3.12 (2.20-3.97)

0.124

2.36 (1.76-3.31)

2.24 (2.07-4.46)

0.376

Postoperative NLR

5.97 (4.28-8.33)

8.48 (5.33-23.3)

0.140

5.96 (4.53-8.54)

6.91 (4.66-15.9)

0.455

5.97 (4.32-8.63)

7.43 (4.95-16.6)

0.247

PreoperativePLR

78.0 (53.6-124)

132 (108-189)

0.003*

79.2 (54.2-128)

123 (92.9-132)

0.102

82.3 (53.9-129)

111 (86.6-131)

0.274

Postoperative PLR

164 (90.8-203)

201 (180-568)

0.018*

160 (90.5-207)

186 (177-560)

0.102

157 (90.2-252)

186 (173-407)

0.111

cT stage^a

T1-2/ 3-4

11/ 18

2/ 10

0.276

10/ 14

2/ 11

0.149

10/ 17

3/ 8

0.714

cN stage^a

N0/ 1-3

16/ 13

4/ 8

0.306

13/ 11

6/ 7

0.737

12/ 15

7/ 4

0.476

cStage^a

Stage I-II/ III-IV

17/ 12

4/ 8

0.181

14/ 10

6/ 7

0.512

14/ 13

6/ 5

1

CRP POD3

11.5 (4.67-17.5)

14.2 (7.12-23.3)

0.547

11.37 (5.43-17.5)

12.1 (3.24-23.2)

0.987

12.2 (4.64-19.6)

12.1 (10.7-21.9)

0.394

Histological type

differentiated/ undifferentiated

14/ 15

8/ 4

0.325

12/ 12

7/ 6

1

15/ 12

5/ 6

0.724

pT stage^a

T1-2/ 3-4

12/ 17

4/ 8

0.734

11/ 13

4/ 9

0.491

11/ 16

4/ 7

1

pN number

0.00 (0.00-3.00)

2.50 (1.75-3.25)

0.065

0.00 (0.00-4.25)

2.00 (0.00-2.00)

0.973

1.00 (0.00-3.00)

1.00 (0.00-4.00)

0.785

pN stage^a

N0/ 1-3

17/ 12

2/ 10

0.019*

13/ 11

5/ 8

0.495

13/ 14

5/ 6

1

pStage^a

Stage I-II/ III-IV

20/ 9

7/ 5

0.719

17/ 7

9/ 4

1

19/ 8

6/ 5

0.457

Lymphatic invasion

absent/ present

19/ 10

4/ 8

0.087

14/ 10

8/ 5

0.460

15/ 12

7/ 4

0.729

Venous invasion

absent/ present

20/ 9

4/ 8

0.045*

13/ 11

9/ 4

0.638

17/ 10

6/ 5

0.722

Operative approach

open/ laparoscopic

20/ 9

6/ 6

0.300

16/ 8

11/ 2

0.440

19/ 8

7/ 4

0.714

Operative procedure

DG or PG/ TG

20/ 9

7/ 5

0.719

19/ 5

6/ 7

0.067

7/ 20

2/ 9

1

Lymphadenectomy

D1 or 1+/ D2

14/ 15

2/ 10

0.084

9/ 15

6/ 7

0.730

10/ 17

6/ 5

0.471

Operative time (min)

251 (223-309)

264 (196-297)

0.764

243 (214-303)

268 (251-306)

0.382

236 (213-304)

267 (246-308)

0.385

Anesthesia time (min)

294 (268-352)

292 (233-315)

0.422

274 (250-333)

312 (279-335)

0.259

277 (250-322)

306 (282-344)

0.311

Bleeding (mL)

140 (20-380)

270 (142-651)

0.105

100 (20-373)

380 (150-750)

0.0502

210 (45-470)

150 (40-683)

0.735

Complications

absent/ present

20/ 9

6/ 6

0.300

17/ 7

8/ 5

0.716

17/ 10

7/ 4

1

Duration of hospitalization (days)

11.0 (10-18)

14.0 (13-20)

0.084

11.5 (10-14)

14 (11-20)

0.291

12.0 (10-18)

13.0 (11-23)

0.457

Adjuvant chemotherapy

absent/ present

16/ 13

3/ 9

0.098

14/ 10

4/ 9

0.17

11/ 16

7/ 4

0.288

Recurrence

absent/ present

24/ 5

5/ 7

0.020*

20/ 4

7/ 6

0.118

21/ 6

7/ 4

0.432

Recurrent style (local/ lymphatic/ hematogenous/ dissemination)

1/ 1/ 1/ 2

0/ 1/ 3/ 5

0.629

1/ 1/ 2/ 2

0/ 0/ 1/ 5

0.318

0/ 0/ 1/ 5

1/ 1/ 2/ 2

0.318